Roche details Gazyva's positive data en route to key lupus nephritis expansion
Roche has detailed results of a phase 3 trial of its blood cancer drug Gazyva in lupus nephritis. The data set up the CD20 antibody for potential approval for what would be its most important indication.
Roche has detailed results of a phase 3 trial of its blood cancer drug Gazyva in lupus nephritis. The data set up the CD20 antibody for potential approval for what would be its most important indication.
